MDGL
MadrigalFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Successful late‑stage readouts and smooth regulatory/commercial execution could re-rate the stock dramatically from the current anchor, driven by high-margin hepatic franchise and limited direct competition.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -13.8.
What can break
Clinical readout misses endpoints or is inconclusive
Momentum
49
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.90 · Bull $7.25 · Bear $0.73
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-16 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $660.07
Why
Momentum49 · Δ7d -13.8
Value41 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
49
34% active weight
Current posture
7d trendSoftening
Δ7d
-13.8
Δ21d
-8.0
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 49.2 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$11.1B
Beta
-1.02
Shares Out
22.71M
P/E (TTM) · Derived
-38.0
P/S (TTM)
18.04
P/FCF (TTM) · Derived
-65.81
Rev YoY
+362.0%
EPS YoY
-3.3%
Gross Margin
+95.3%
Op Margin
-41.9%
Net Debt
-$808.68M
Current Ratio
3.44
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology